ReviewThe European respiratory journal2015
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Registry-linked trialAbstract readReview
In one paragraph
Review in The European respiratory journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03302299 (URBAN ARCH), which is not on this map. Cited by 281 papers, 18 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
281citing papers in PubMed, 18 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence
Who cites it
281 citing papers in PubMed, 18 syntheses or guidelines pooled it.
- Prevalence of latent tuberculosis infection in Malaysia: the first systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Multidimensional determinants of BCG-induced false-positivity in tuberculin skin testing: a global meta-analysis of 242 studies.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Prevalence of Tuberculosis among migrants under national screening programs: a systematic review and meta-analysis.Global health research and policy · 2025Pooled it
- Brazilian recommendations for the management of tuberculosis infection in immune-mediated inflammatory diseases.Advances in rheumatology (London, England) · 2025Guideline
- Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review.Revista da Sociedade Brasileira de Medicina Tropical · 2024Pooled it
- Risk of Tuberculosis Disease in People With Chronic Kidney Disease Without Kidney Failure: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Pooled it
- The performance of interferon gamma release assays in patients with nontuberculous mycobacterial infection: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Pooled it
- Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials.Archives of public health = Archives belges de sante publique · 2023Pooled it
- Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- The Association Between Diabetes Mellitus and the Risk of Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.Journal of the Chinese Medical Association : JCMA · 2021Pooled it
- Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.Nature medicine · 2020Pooled it
- Is interleukin-2 an optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis.Annals of medicine · 2020Pooled it
- Pooled it
- Does phone messaging improves tuberculosis treatment success? A systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- Prevention of tuberculosis in household members: estimates of children eligible for treatment.Bulletin of the World Health Organization · 2019Pooled it
- Latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis on TST and IGRA.Infection · 2019Pooled it
- Migrant Healthcare Guidelines: A Systematic Quality Assessment.Journal of immigrant and minority health · 2019Pooled it
- Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Latent Tuberculosis and Associated Factors Among Adults Living With HIV in Kinshasa, Democratic Republic of the Congo: A Cross-Sectional Study.Public health challenges · 2026Article
221 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
72 authors.
Haileyesus GetahunThe Global TB Programme, World Health Organization, Geneva, Switzerland getahunh@who.int.
Alberto MatteelliThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Ibrahim AbubakarDept of Infection and Population Health, University College London, London, UK Public Health England, London, UK.
Mohamed Abdel AzizWorld Health Organization, Regional Office for Eastern Mediterranean, Egypt.
Annabel BaddeleyThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Draurio BarreiraNational TB Programme, Ministry of Health, Brasilia, Brazil.
Saskia Den BoonIndependent consultant, Switzerland.
Susana Marta Borroto GutierrezPedro Kourí Institute of Tropical Medicine, La Habana, Cuba.
Judith BruchfeldUnit of Infectious Diseases, Dept of Medicine, Karolinska Institute Solna and Karolinska University Hospital, Stockholm, Sweden.
Erlina BurhanDept of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia and Persahabatan Hospital, Jakarta, Indonesia.
Solange CavalcanteEvandro Chagas National Institute of Infectious Diseases, FIOCRUZ, Rio de Janeiro, Brazil.
Rolando CedillosHospital Nacionale Rosales, San Salvador, El Salvador.
Richard ChaissonCenter for TB Research, John Hopkins University, Baltimore, MD, USA.
Cynthia Bin-Eng CheeTan Tock Seng Hospital, Singapore.
Lucy ChesireTB Advocacy Consortium, Nairobi, Kenya.
Elizabeth CorbettLondon School of Hygiene and Tropical Medicine, Blantyre, Malawi.
Masoud DaraWorld Health Organization, Regional Office for Europe, Denmark.
Justin DenholmVictorian Tuberculosis Program, Melbourne, Australia.
Gerard de VriesKNCV Tuberculosis Foundation, Den Haag, The Netherlands.
Dennis FalzonThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Nathan FordDept of HIV and Global Hepatitis Programme, World Health Organization, Switzerland.
Margaret Gale-RowePublic Health Agency of Canada, Ottawa, ON, Canada.
Chris GilpinThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Enrico GirardiIstituto Nazionale Malattie Infettive L. Spallanzani, Rome, Italy.
Un-Yeong GoDept of HIV/AIDS and TB Control Korea, Korea Centers for Disease Control and Prevention, Republic of Korea.
Darshini GovindasamyHealth Systems Research Unit, South African Medical Research Council, South Africa.
Alison D GrantDept of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
Malgorzata GrzemskaThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Ross HarrisPublic Health England, London, UK.
C Robert HorsburghDept of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
Asker IsmayilovMain Medical Department, Ministry of Justice, Azerbaijan.
Ernesto JaramilloThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Sandra KikMcGill International TB Centre, and Dept of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada.
Katharina KranzerDept of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
Christian LienhardtThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Philip LoBueCenters for Disease Control and Prevention, USA.
Knut LönnrothThe Global TB Programme, World Health Organization, Geneva, Switzerland Dept of Public Health Sciences, Karolinska Institute, Solna, Sweden.
Guy MarksWoolcock Institute of Medical Research University of Sydney and UNSW Australia, Sydney, Australia.
Dick MenziesMcGill International TB Centre, and Dept of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada.
Giovanni Battista MiglioriWHO Collaborating Center for TB and Lung Diseases Fondazione S. Maugeri, Tradate, Italy.
Davide MoscaMigration Health Department, International Organization of Migration, Geneva, Switzerland.
Ya Diul MukadiInfectious Disease Division, Bureau for Global Health, US Agency for International Development, Washington, DC, USA.
Alwyn MwingaZambart Project, Lusaka, Zambia.
Lisa NelsonDept of HIV and Global Hepatitis Programme, World Health Organization, Switzerland.
Nobuyuki NishikioriWorld Health Organization, Regional Office for the Western Pacific, Philippines.
Anouk Oordt-SpeetsPallas Health Research and Consultancy BV, Rotterdam, The Netherlands.
Molebogeng Xheedha RangakaDept of Infection and Population Health, University College London, London, UK Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Andreas ReisKnowledge, Ethics and Research Department, World Health Organization, Switzerland.
Lisa RotzCenters for Disease Control and Prevention, USA.
Andreas SandgrenEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Monica Sañé SchepisiIstituto Nazionale Malattie Infettive L. Spallanzani, Rome, Italy.
Holger J SchünemannDept of Clinical Epidemiology and Biostatistics and Dept of Medicine, GRADE Center, McMaster University, Hamilton, ON, Canada.
Surender Kumar SharmaKnowledge, Ethics and Research Department, World Health Organization, Switzerland.
Giovanni SotgiuEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Helen R StaggDept of Infection and Population Health, University College London, London, UK.
Timothy R SterlingVanderbilt University School of Medicine, Nashville, TN, USA.
Tamara TayebNational TB Programme, Ministry of Health, Riyadh, Saudi Arabia.
Mukund UplekarThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Marieke J van der WerfEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Wim VandeveldeEuropean AIDS Treatment Group, Brussels, Belgium.
Femke van KesselPallas Health Research and Consultancy BV, Rotterdam, The Netherlands.
Anna van't HoogAcademic Medical Centre, University of Amsterdam, Dept of Global Health, Amsterdam, The Netherlands.
Jay K VarmaCenters for Disease Control and Prevention, USA.
Natalia VezhninaHIV/TB and Penal System Projects, Russian Federation.
Constantia VoniatisClinical Laboratories, Ministry of Health, Nicosia, Cyprus.
Marije Vonk Noordegraaf-SchoutenPallas Health Research and Consultancy BV, Rotterdam, The Netherlands.
Diana WeilThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Karin WeyerThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Robert John WilkinsonInstitute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa Francis Crick Institute Mill Hill Laboratory, Dept of Medicine, Imperial College London, London, UK.
Takashi YoshiyamaFukujuji Hospital, Japan Anti Tuberculosis Association, Tokyo, Japan.
Jean Pierre ZellwegerTuberculosis Competence Centre, Berne, Switzerland.
Mario RaviglioneThe Global TB Programme, World Health Organization, Geneva, Switzerland.
Funding
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0MDepartment of Health SRF-2011-04-001Intramural CDC HHS CC999999NIAID NIH HHS P30 AI094189Wellcome Trust 091769Wellcome Trust 104803
Abstract
Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3-4 month isoniazid plus rifampicin; or 3-4 month rifampicin alone.
Indexed as
Antirheumatic AgentsAntitubercular AgentsCoinfectionComorbidityDisease ManagementDrug UsersEmigrants and ImmigrantsEvidence-Based MedicineHealth PersonnelHIV InfectionsHumansIll-Housed PersonsInterferon-gamma Release TestsIsoniazidKidney Failure, ChronicLatent TuberculosisAntirheumatic AgentsAntitubercular AgentsIsoniazidRifampinrifapentineTumor Necrosis Factor-alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03302299ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.